Note 17 - Segments (Tables)

12 Months Ended

Dec. 31, 2019

Year Ended December 31, 2019	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	16,665		$	—		$	—		$	16,665
License revenue		9,953			—			—			9,953
Grant and other revenue		384,776			246,432			—			631,208
Total revenue		411,394			246,432			—			657,826
Cost of revenue		6,667			—			—			6,667
Research and development expenses, excluding depreciation and amortization		4,795,445			542,822			—			5,338,267
Selling, general and administrative expenses, excluding depreciation and amortization ( 1 )		—			16,990			6,113,907			6,130,897
Depreciation and amortization ( 2 )		—			—			144,512			144,512
Loss from operations ( 3 )		(4,390,718	)		(313,380	)		(6,258,419	)		(10,962,517	)
Other income ( 4 )		—			—			17,675			17,675
Provision for income taxes		(284	)		(20	)		(403	)		(707	)
Loss from continuing operations		(4,391,002	)		(313,400	)		(6,241,147	)		(10,945,549	)
Loss from discontinued operations, net of tax effect		(2,665	)		—			—			(2,665	)
Net loss		(4,393,666	)		(313,400	)		(6,241,147	)		(10,948,214	)
Total assets, net of depreciation and amortization:
United States	$	55,229		$	31,449		$	4,064,228		$	4,150,906
International		—			—			—			—
Capital expenditures		—			—			1,258			1,258

Year Ended December 31, 2018	Diagnostics			Therapeutics			Corporate			Total
Royalty revenue	$	15,347		$	—		$	—		$	15,347
License revenue		307,174			—			—			307,174
Grant and other revenue		494,997			351,833			—			846,830
Total revenue		817,518			351,833			—			1,169,351
Cost of revenue		96,636			—			—			96,636
Research and development expenses		3,064,115			1,157,766			—			4,221,881
Selling, general and administrative expenses, excluding depreciation and amortization ( 1 )		—			78,606			7,469,144			7,547,750
Depreciation and amortization ( 2 )		—			—			150,385			150,385
Loss from operations ( 3 )		(2,343,233	)		(884,539	)		(7,619,529	)		(10,847,301	)
Other expense ( 4 )		—			—			(5,321,270	)		(5,321,270	)
Benefit from income taxes		1,413			534			7,806			9,753
Loss from continuing operations		(2,341,820	)		(884,005	)		(12,932,993	)		(16,158,818	)
Income from discontinued operations, net of tax effect		1,449			—			—			1,449
Gain on sale of discontinued operations, net of tax effect		43,053			—			—			43,053
Net loss		(2,297,318	)		(884,005	)		(12,932,993	)		(16,114,316	)
Total assets, net of depreciation and amortization:
United States	$	91,425			24,763			6,878,129			6,994,317
International		14,330						381			14,711
Capital expenditures		—			—			46,192			46,192